| Literature DB >> 26631755 |
Ping Feng1, Hong Zhang1, Zhuqiu Zhang2, Xiaoli Dai1, Ting Mao1, Yinyin Fan1, Xiaofang Xie1, Huiyan Wen1, Peijuan Yu1, Yae Hu3, Ruhong Yan4.
Abstract
The immune costimulatory molecule B7-H3 has been shown to be involved in the regulation of murine bone formation. However, the role of B7-H3 in bone metabolic diseases remains unknown. In our study, matrix metalloproteinase 2 (MMP-2) and soluble B7-H3 (sB7-H3) were found to be correlatively up-regulated in the sera of osteoporosis patients. Furthermore, our results showed that MG63 cells treated with MMP-2 inhibitors produced lower amounts of sB7-H3 while cells with recombinant MMP-2 had an increased membrane B7-H3 (mB7-H3) shedding. Therefore, elevated MMP-2 levels resulted in an elevation of serum sB7-H3 and reduction of osteoblastic mB7-H3. B7-H3 knockdown in MG63 cells significantly decreased osteoblastic markers and substantially decreased the number of mineralized nodules after 21days. Thus, B7-H3-deficient MG63 cells exhibited impaired bone formation. These results suggest that mB7-H3 is required for the later phases of osteoblast differentiation and that MMP-2/B7-H3 plays a negative regulatory role in osteoporosis.Entities:
Keywords: Bone; Matrix metalloproteinases; Osteoporosis; Soluble B7-H3
Mesh：
Substances：
Year: 2015 PMID： 26631755 DOI： 10.1016/j.clim.2015.11.009
Source DB: PubMed Journal: Clin Immunol ISSN： 1521-6616 Impact factor: 3.969